Beijing Sun-Novo Pharmaceutical Research (688621.SS) Earnings Analysis

Beijing Sun-Novo Pharmaceutical Research (688621.SS) has no confirmed upcoming earnings date. Trailing P/E 33.50.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 688621.SS next report earnings?

No confirmed upcoming earnings date is currently scheduled for 688621.SS. This page updates as the calendar is published.

688621.SS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-240.18 CNYn/an/an/a
2026-02-270.3 CNYn/an/an/a
2025-10-300.3061 CNYn/an/an/a
2025-04-250.27 CNYn/an/an/a
2025-02-27-0.27035 CNYn/an/an/a
2024-10-280.528 CNYn/an/an/a
2024-08-290.677 CNYn/an/an/a

688621.SS valuation and analyst view

Trailing P/E33.50
Trailing EPS1.633 CNY
Price / book5.21
Dividend yield0.33%
Market cap6.40B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Beijing Sun-Novo Pharmaceutical Research (688621.SS)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for 688621.SS. This page updates as the calendar is published.

Did 688621.SS beat earnings last quarter?

Consensus estimate data was not available for 688621.SS's 2026-04-24 report.

What is 688621.SS's current P/E ratio and EPS?

688621.SS trades at a trailing P/E of 33.50 on trailing EPS of 1.6327075246824148 CNY.

What do analysts rate 688621.SS?

688621.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.